Importance Some recently proposed frontline therapies for malignant pleural mesothelioma
(MPM) are very costly, yet their impact on quality of life and overall survival of these patients …

Introduction Malignant pleural mesothelioma (MPM) is an aggressive malignancy that affects
older adults with frequent comorbidities, making real-world treatment decisions challenging …

Introduction: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab (NI)
versus pemetrexed plus cisplatin/carboplatin (C) as the first-line treatment for unresectable …

Background In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus
ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with …

Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …

Background Approved systemic treatments for malignant pleural mesothelioma (MPM) have
been limited to chemotherapy regimens that have moderate survival benefit with poor …

In inoperable pleural mesothelioma, pemetrexed+ cisplatin as first line is considered the
standard of care, but novel treatments have been recently proposed. Our objective was to …

Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy
characterised by limited treatment options and a poor prognosis. At relapse after platinum …

The management of pleural mesothelioma has changed with the demonstration that first-line
checkpoint blockade therapy improves survival. This review covers issues of relevance to …

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for
Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic …